Publications

1. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial [May 2024]

2. Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR [2021]

3. Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells [2021]

4. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies [2020]

5. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy [2020]

6. Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells [2020]

7. Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch [2019]

8. First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial [2018]

9. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia [2018]

10. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells [2017]

11. A compound chimeric antigen receptor strategy for targeting multiple myeloma [2017]

12. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor [2017]

13. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies [2016]

14. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells [2016]